Related Experiment Video
Updated: Oct 14, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Immunohistochemical Expression of CD200 in Renal Cell Carcinoma
Hala M El Hanbuli1, Heba A Ibrahim2, Somia A M Soliman2
1Department of Pathology, Faculty of Medicine, Fayoum University, Faiyum, Egypt.
Background And Objectives:
Renal cell carcinoma (RCC) is the most common malignant renal neoplasm in adults. CD200 is a transmembrane protein and is a promising target for cancer immunotherapy. The aim of this study is to assess the CD200 expression in RCC.
Materials And Methods:
Eighty paraffin-embedded radical nephrectomy specimens, diagnosed with RCC were evaluated immunohistochemically for CD200 expression.
Results:
Out of eighty cases studied, CD200 was expressed in n = 73 cases (91.25%) with high intensity in 27 cases (33.75%), moderate intensity in 22 cases (27.5%), and mild intensity in 24 cases (30%). No staining was observed in the adjacent apparently normal renal tissue in all examined sections. No significant relationship was found between CD200 expression and the gender, tumor size, tumor side, histologic type, nuclear grade, T stage, and tumor necrosis.
Conclusion:
CD200 expression in most of the studied cases of RCC may refer to the potential therapeutic of anti-CD200 antibody for this cancer.
Insights
CD200 is highly expressed in most renal cell carcinoma (RCC) cases, suggesting anti-CD200 antibody therapy could be a potential treatment for this common adult cancer.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Renal cell carcinoma (RCC) is the most frequent malignant tumor affecting the kidney in adults.
- CD200, a transmembrane protein, is recognized as a potential target for cancer immunotherapy.
Purpose of the Study:
- To investigate and quantify the expression of CD200 in renal cell carcinoma (RCC).
- To evaluate the potential of CD200 as a therapeutic target in RCC.
Main Methods:
- Immunohistochemical analysis was performed on 80 radical nephrectomy specimens diagnosed with RCC.
- CD200 expression levels (intensity and presence) were assessed in tumor tissues.
Main Results:
- CD200 expression was detected in 91.25% (73 out of 80) of the studied RCC cases.
- High, moderate, and mild intensities of CD200 staining were observed in 33.75%, 27.5%, and 30% of cases, respectively.
- No CD200 staining was found in adjacent normal renal tissue, and expression did not correlate with clinical or pathological features.
Conclusions:
- The high prevalence of CD200 expression in RCC suggests its potential as a therapeutic target.
- Anti-CD200 antibody therapy may offer a promising treatment strategy for patients with renal cell carcinoma.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
06:29Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025